Golimumab in the treatment of psoriatic arthritis: efficacy and safety
Tumor necrosis factor-α (TNF-α) holds a central position in the pathogenesis of autoimmune inflammatory diseases of the locomotor apparatus. A separate class of drugs, namely, TNF-α inhibitors, that are effective against multicomponent diseases, such as psoriatic arthritis (PsA), is now available to...
Saved in:
| Main Authors: | Tatiana Viktorovna Korotaeva, E. Yu. Loginova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2015-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/639 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues
by: N. V. Chichasova
Published: (2016-06-01) -
Efficacy of golimumab in treating uveitis in patients with ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2016-09-01) -
Golimumab in the treatment of inflammatory diseases: A role of immunogenicity
by: D. E. Karateev
Published: (2016-01-01) -
Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01) -
Time course of changes in lipid profile measures in patients with early psoriatic arthritis during adalimumab therapy
by: E. I. Markelova, et al.
Published: (2019-11-01)